Incyte | INCY - SCHULD

Aktienkurs
91.57
Täglich Wechseln
-0.69 -0.75%
Monatlich
-8.47%
Jährlich
51.11%
Q1 Prognose
89.46




SCHULD Veränderung Datum
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agenus USD 35.54M 2.34M 2025-03
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amgen USD 54.59B 1.62B 2025-09
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Biogen USD 6.29B 1.7M 2025-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Exelixis USD 176.46M 3.38M 2025-09
Gilead Sciences USD 24.94B 5M 2025-09
Incyte USD 40.41M 855K 2025-12
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
MacroGenics USD 37.01M 238K 2025-09
Merck USD 41.37B 5.97B 2025-09
Moderna USD 734M 7M 2025-09
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novartis USD 32.64B 1.37B 2025-06
Novartis USD 32.02B 615M 2025-09
Pfizer USD 60.85B 78M 2025-09
PTC Therapeutics USD 286.32M 306K 2025-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
Vertex Pharmaceuticals USD 1.83B 307.4M 2025-09